Drug Trial Radar · NCT06217952
Safety, Tolerability, and Pharmacokinetics of SPL84 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jan 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Feb 5, 2023
Primary completion
Aug 6, 2023
Study completion Aug 6, 2023
Sponsor
- Lead sponsor
- SpliSense Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of SPL84 single ascending doses (SAD) in healthy volunteers (HV)
Conditions
- Cystic Fibrosis
Interventions
SPL84Drug
SPL84 solution for nebulization
PlaceboOther
Placebo solution for nebulization
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of SPL84 as evaluated by number of subjects with at least one treatment-related adverse event (AE) or serious adverse event (SAEs)Time frame: Day 1 through Day 31
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal heart rateTime frame: Day 1 through Day 31
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal respiratory rateTime frame: Day 1 through Day 31
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal systolic and diastolic blood pressureTime frame: Day 1 through Day 31
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal oximetryTime frame: Day 1 through Day 31
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal temperatureTime frame: Day 1 through Day 31
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal hematology lab test resultsTime frame: Day 1 through Day 31
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal biochemistry lab test resultsTime frame: Day 1 through Day 31
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal urinalysis lab test resultsTime frame: Day 1 through Day 31
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal electrocardiogram (ECG) parametersTime frame: Day 1 through Day 31
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal physical examination findingsTime frame: Day 1 through Day 31
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal Pulmonary function tests resultsTime frame: Day 1 through Day 31
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hadassah Ein Kerem Hospital Clinical Research Center
Jerusalem, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.